Foresee Pharmaceuticals Co., Ltd. (TPEX: 6576)

Market Cap	10.75B
Revenue (ttm)	327.18M
Net Income (ttm)	-859.00M
Shares Out	135.96M
EPS (ttm)	-6.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,462
Open	80.30
Previous Close	79.60
Day's Range	78.60 - 80.30
52-Week Range	68.40 - 107.50
Beta	1.14
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About Foresee Pharmaceuticals

Foresee Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatm...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6576

Financial Performance

In 2023, Foresee Pharmaceuticals's revenue was 195.04 million, a decrease of -35.31% compared to the previous year's 301.51 million. Losses were -1.04 billion, 119.3% more than in 2022.